Cerulean reported in-line Q3 results on 16 November followed by an investor call highlighting its growing clinical program for treatments using its unique nanoparticle drug conjugation NDC delivery system. If successful, lead compound CRLX101 will launch as a new mechanism of action in third- and fourth-line renal cell cancer where there are few treatment options. Its technology holds the potential for numerous NDC combinations with currently marketed drugs, underlined by its newly announced
19 Nov 2015
Collaborating with big pharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Collaborating with big pharma
- Published:
19 Nov 2015 - Author:
- Pages:
Cerulean reported in-line Q3 results on 16 November followed by an investor call highlighting its growing clinical program for treatments using its unique nanoparticle drug conjugation NDC delivery system. If successful, lead compound CRLX101 will launch as a new mechanism of action in third- and fourth-line renal cell cancer where there are few treatment options. Its technology holds the potential for numerous NDC combinations with currently marketed drugs, underlined by its newly announced